Henry Castro
Novartis
9 Papers
27 Citations
Henry Castro is an academic researcher from Novartis. The author has contributed to research in topics: Sonidegib & Internal medicine. The author has an hindex of 4, co-authored 8 publications. Previous affiliations of Henry Castro include Bristol-Myers Squibb.
Chat about Author
Papers
Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study
John T. Lear,Michael R. Migden,Karl D. Lewis,Anne Lynn S. Chang,Alexander Guminski,Ralf Gutzmer,Luc Dirix,Patrick Combemale,Alexandros Stratigos,Ruth Plummer,Henry Castro,Tingting Yi,Manisha Mone,Jocelyn Zhou,Uwe Trefzer,Martin Kaatz,Carmen Loquai,Ragini R. Kudchadkar,Dalila Sellami,Reinhard Dummer +19 more
TL;DR: Patients with locally advanced basal cell carcinoma (laBCC) or metastatic BCC (mBCC), two difficult‐to‐treat populations, have had limited treatment options.
175
Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers.
Jocelyn Zhou,Michelle Quinlan,Kelli J Glenn,Hildegard Boss,Franck Picard,Henry Castro,Dalila Sellami +6 more
TL;DR: A modest reduction in the extent of sonidegib absorption by esomeprazole is suggested, and there was no obvious metabolic drug-drug interaction between the two agents.
16
Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: A trial in progress.
Simon Chowdhury,Joaquin Mateo,Mitchell E. Gross,Andrew J. Armstrong,Marcia Cruz-Correa,Josep M. Piulats,Jean-Yves Blay,Miao Li,Delcia Rivas,Luis Quintero,Henry Castro,Andong Nkobena,Mitch Raponi,Robert Pelham,Mark Landers,Robert B. Montgomery +15 more
TL;DR: A novel liquid biopsy test (EPIC Sciences) identifies men with mCRPC who have a BRCA1/2 mutation or mutations in other genes resulting in HRD with poor prognosis.
7
Efficacy and safety of sonidegib in patients (pts) with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC): BOLT 30-month analysis.
Reinhard Dummer,Michael R. Migden,Alexander Guminski,Ralf Gutzmer,Ragini R. Kudchadkar,Karl D. Lewis,Luc Dirix,Patrick Combemale,Uwe Trefzer,Carmen Loquai,Martin Kaatz,Anne Lynn S. Chang,Alexander J. Stratigos,Elizabeth Ruth Plummer,Manisha Mone,Henry Castro,Tingting Yi,Dalila Sellami,John T. Lear +18 more
TL;DR: Sonidegib 200 mg was approved for use in pts with advanced BCC or laBCC not amenable to surgery/radiotherapy based on results from BOLT (NCT01327053).
2
Investigator-assessed efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma and metastatic basal cell carcinoma: results of the BOLT 30-month analysis
John T. Lear,Alexander Guminski,Ralf Gutzmer,Michael R. Migden,Ragini R. Kudchadkar,Karl D. Lewis,Luc Dirix,Ruth Plummer,Alexandros Stratigos,Anne Lynn S. Chang,Uwe Trefzer,Carmen Loquai,Martin Kaatz,Patrick Combemale,Manisha Mone,Henry Castro,Tingting Yi,Dalila Sellami,Reinhard Dummer +18 more
- 01 Jan 2016
1